All In Biotech

NDA 212576 · Taiho Oncology

Inqovi

Cedazuridine, Decitabine · Oral · Nucleoside Metabolic Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jul 7, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

80

3 Phase 3, 31 recruiting

FAERS reports

979

804 serious, 188 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 25, 2026.

INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. ( 1.1 ) In combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 ) 1.1 Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. 1.2 Acute Myeloid Leukemia INQOVI is indicated in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Mechanism: Decitabine is a nucleoside metabolic inhibitor that is believed to exert its effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation and/or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in cancer cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 13, 2026 Supplement 8 · Efficacy OrphanLetterLabel
  • Jul 7, 2020 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelOrphanLabelLetterReview
1 products under this application
  • INQOVI · CEDAZURIDINE 100MG; DECITABINE 35MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cedazuridine" as an intervention, any sponsor and status, largest first.

All 80 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue144
  • inappropriate schedule of product administration142
  • cytopenia129
  • product use in unapproved indication120
  • platelet count decreased115
  • death114
  • white blood cell count decreased92
  • off label use78
  • nausea73
  • transfusion71
  • haemoglobin decreased62
  • asthenia58

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202026
2021115
202264
202354
2024137
2025308
2026275

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inqovi (Decitabine/Cedazuridine)

2024 spending

$94.5M

Beneficiaries

2,928

12,036 claims

Per beneficiary

$32,276

$1,616.93 per unit

View as table
YearSpending
2020$9,070,838
2021$53,167,043
2022$69,638,922
2023$77,261,469
2024$94,503,101

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Taiho Oncology

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.